Shigetoshi Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shigetoshi Yoshida has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Ichiro Yoshino
Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
12 shared publications - Takekazu Iwata
Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
6 shared publications Makoto Suzuki
5 shared publications- Hironobu Wada
Department of Thoracic Surgery, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan
4 shared publications - Kiyoshi Shibuya
Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
4 shared publications - Takahiro Nakajima
Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
4 shared publications
Latest Publications
- 1 October 2016
- Vol. 69 (11) , 923-929
[The History and Development of Experimental Rodent Models of Chronic Lung Allograft Dysfunction after Lung Transplantation].
Chronic lung allograft dysfunction (CLAD) is a critical impediment to the long-term survival after lung transplantation. A rat orthotopic lung transplantation model was developed in the early 1970s, and using this model, our laboratory has shown that the immunopathogenesis of CLAD involves both allogeneic immunity and autoimmunity. However, further investigation of CLAD is limited by the scarcity of transgenic and knockout strains. The model most widely used to study CLAD, the mouse model of heterotopic tracheal transplantation, has some incomplete pathophysiologic features of CLAD, which limits the utility of this model. Unlike other solid organ transplants, vascularized and aerated murine lung transplantation has only recently been developed. We have also reported that minor, but not major, histocompatibility antigens mismatch induced the development of CLAD in murine orthotopic lung transplants and that CLAD development was interleukin-17-dependent. This mini-review underscores the history and development of rodent models of CLAD after lung transplant, including the findings from our previous studies. In addition, the future direction of rodent models is also discussed.
- 1 October 2016
- Vol. 69 (11) , 923-929
[The History and Development of Experimental Rodent Models of Chronic Lung Allograft Dysfunction after Lung Transplantation].
Chronic lung allograft dysfunction (CLAD) is a critical impediment to the long-term survival after lung transplantation. A rat orthotopic lung transplantation model was developed in the early 1970s, and using this model, our laboratory has shown that the immunopathogenesis of CLAD involves both allogeneic immunity and autoimmunity. However, further investigation of CLAD is limited by the scarcity of transgenic and knockout strains. The model most widely used to study CLAD, the mouse model of heterotopic tracheal transplantation, has some incomplete pathophysiologic features of CLAD, which limits the utility of this model. Unlike other solid organ transplants, vascularized and aerated murine lung transplantation has only recently been developed. We have also reported that minor, but not major, histocompatibility antigens mismatch induced the development of CLAD in murine orthotopic lung transplants and that CLAD development was interleukin-17-dependent. This mini-review underscores the history and development of rodent models of CLAD after lung transplant, including the findings from our previous studies. In addition, the future direction of rodent models is also discussed.
- Open Access
- 22 July 2016
- Published by Springer Nature in Respiratory Research
- Vol. 17 (1) , 1-8
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)
Idiopathic pulmonary fibrosis (IPF) often accompanies lung cancer, and life-threatening acute exacerbation (AE) of IPF (AE-IPF) is reported to occur in 20 % of IPF patients who undergo lung cancer surgery. Pirfenidone is an anti-fibrotic agent known to reduce disease progression in IPF patients. A phase II study was conducted to evaluate whether perioperative pirfenidone treatment could reduce the incidence of postoperative AE-IPF patients with lung cancer. Pirfenidone was orally administered to IPF patients who were candidates for lung cancer surgery; pirfenidone was dosed at 600 mg/day for the first 2 weeks, followed by 1200 mg/day. Surgery was performed after at least 2 weeks of 1200-mg/day administration. The primary endpoint was non–AE-IPF rate during postoperative days 0–30, compared to the null value of 80 %, and the secondary endpoint was safety. Radiologic and pathologic diagnoses of IPF and AE-IPF were confirmed by an independent review committee. From June 2012 to January 2014, 43 cases were enrolled, and 39 were eligible (full analysis set [FAS]). Both pirfenidone treatment and surgery were performed in 36 patients (per protocol set [PPS]). AE-IPF did not occur in 37/39 patients (94.9 % [95 % confidential interval: 82.7–99.4 %, p = 0.01]) in the FAS, and in 38/39 patients (97.2 % [95 % confidential interval: 85.5–99.9 %, p = 0.004] in the PPS. A grade 5 adverse event (death) occurred in 1 patient, after AE-IPF; no other grade 3–5 adverse events were observed. Perioperative pirfenidone treatment is safe, and is promising for reducing AE-IPF after lung cancer surgery in IPF patients. This clinical trial was registered with the University Hospital Medical Information Network (UMIN) on April 16th, 2012 (Registration Number: UMIN000007774 ).
- 22 July 2016
- Published by Springer Nature in Respiratory Research
- Vol. 17 (1) , 1-8
Open AccessA phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)
Idiopathic pulmonary fibrosis (IPF) often accompanies lung cancer, and life-threatening acute exacerbation (AE) of IPF (AE-IPF) is reported to occur in 20 % of IPF patients who undergo lung cancer surgery. Pirfenidone is an anti-fibrotic agent known to reduce disease progression in IPF patients. A phase II study was conducted to evaluate whether perioperative pirfenidone treatment could reduce the incidence of postoperative AE-IPF patients with lung cancer. Pirfenidone was orally administered to IPF patients who were candidates for lung cancer surgery; pirfenidone was dosed at 600 mg/day for the first 2 weeks, followed by 1200 mg/day. Surgery was performed after at least 2 weeks of 1200-mg/day administration. The primary endpoint was non–AE-IPF rate during postoperative days 0–30, compared to the null value of 80 %, and the secondary endpoint was safety. Radiologic and pathologic diagnoses of IPF and AE-IPF were confirmed by an independent review committee. From June 2012 to January 2014, 43 cases were enrolled, and 39 were eligible (full analysis set [FAS]). Both pirfenidone treatment and surgery were performed in 36 patients (per protocol set [PPS]). AE-IPF did not occur in 37/39 patients (94.9 % [95 % confidential interval: 82.7–99.4 %, p = 0.01]) in the FAS, and in 38/39 patients (97.2 % [95 % confidential interval: 85.5–99.9 %, p = 0.004] in the PPS. A grade 5 adverse event (death) occurred in 1 patient, after AE-IPF; no other grade 3–5 adverse events were observed. Perioperative pirfenidone treatment is safe, and is promising for reducing AE-IPF after lung cancer surgery in IPF patients. This clinical trial was registered with the University Hospital Medical Information Network (UMIN) on April 16th, 2012 (Registration Number: UMIN000007774 ).
- Open Access
- 24 April 2015
- Published by Springer Nature in Surgical Case Reports
- Vol. 1 (1) , 1-4
Late recurrence of a tumor of Ewing’s sarcoma family of tumors: report of a case
A 27-year-old female presented with a history of a right chest wall tumor at 3 years of age. At that time, the tumor was surgically resected and diagnosed as Ewing’s sarcoma (EWS), and postoperative chemoradiotherapy was administered. The patient remained disease-free for 25 years. At age 27, chest computed tomography revealed a mass adjacent to the anterolateral thoracic wall. After surgery, the diagnosis was primitive neuroectodermal tumor (PNET). She died of the disease 10 months later. PNET and EWS were integrated into a single item in the 2002 WHO classification; thus, they are considered clinically and pathologically identical. The morphologic, immunohistochemical, and molecular biological characteristics of both specimens showed that the second tumor was a local recurrence of Ewing’s sarcoma family of tumors (ESFT). Our case is the longest duration local recurrence reported. Long-term recurrences of ESFT and patients with recurrent ESFT have a poor prognosis; thus, long-term follow-up is necessary.
- 24 April 2015
- Published by Springer Nature in Surgical Case Reports
- Vol. 1 (1) , 1-4
Open AccessLate recurrence of a tumor of Ewing’s sarcoma family of tumors: report of a case
A 27-year-old female presented with a history of a right chest wall tumor at 3 years of age. At that time, the tumor was surgically resected and diagnosed as Ewing’s sarcoma (EWS), and postoperative chemoradiotherapy was administered. The patient remained disease-free for 25 years. At age 27, chest computed tomography revealed a mass adjacent to the anterolateral thoracic wall. After surgery, the diagnosis was primitive neuroectodermal tumor (PNET). She died of the disease 10 months later. PNET and EWS were integrated into a single item in the 2002 WHO classification; thus, they are considered clinically and pathologically identical. The morphologic, immunohistochemical, and molecular biological characteristics of both specimens showed that the second tumor was a local recurrence of Ewing’s sarcoma family of tumors (ESFT). Our case is the longest duration local recurrence reported. Long-term recurrences of ESFT and patients with recurrent ESFT have a poor prognosis; thus, long-term follow-up is necessary.
- Open Access
- 5 February 2015
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 9 (1) , 23
Hybrid video-assisted thoracoscopic surgery lobectomy of fissureless congenital cystic adenomatoid malformation: a case report.
- 5 February 2015
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 9 (1) , 23
Open AccessHybrid video-assisted thoracoscopic surgery lobectomy of fissureless congenital cystic adenomatoid malformation: a case report.
- 1 February 2015
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (2) , 576-577
Endobronchial elastography in the evaluation of esophageal invasion
- 1 February 2015
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (2) , 576-577
Endobronchial elastography in the evaluation of esophageal invasion
- 25 November 2014
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 63 (07) , 614-617
Sarcomatous Components May Predict Prognosis in Patients with Pulmonary Pleomorphic Carcinoma
Objectives and Methods Pulmonary pleomorphic carcinoma often presents with clinically aggressive behavior. We retrospectively reviewed 16 patients who underwent surgery from 1999 to 2013. Results Sarcomatous components included spindle cell type in six (38%) patients, giant cell type in three (19%) patients, and mixed cell type in seven (44%) patients. The 5-year overall survival rate was 40.6%. On univariate analysis, spindle cell type, pN0, and small tumor diameter were associated with better prognosis. The 5-year survival of six patients with spindle cell type was 83.3%. Conclusions Despite the small sample size, we suggest that patients with spindle cell type may have favorable prognoses.
- 25 November 2014
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 63 (07) , 614-617
Sarcomatous Components May Predict Prognosis in Patients with Pulmonary Pleomorphic Carcinoma
Objectives and Methods Pulmonary pleomorphic carcinoma often presents with clinically aggressive behavior. We retrospectively reviewed 16 patients who underwent surgery from 1999 to 2013. Results Sarcomatous components included spindle cell type in six (38%) patients, giant cell type in three (19%) patients, and mixed cell type in seven (44%) patients. The 5-year overall survival rate was 40.6%. On univariate analysis, spindle cell type, pN0, and small tumor diameter were associated with better prognosis. The 5-year survival of six patients with spindle cell type was 83.3%. Conclusions Despite the small sample size, we suggest that patients with spindle cell type may have favorable prognoses.
- 22 November 2014
- Published by Springer Nature in Surgery Today
- Vol. 45 (10) , 1263-1270
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated.
- 22 November 2014
- Published by Springer Nature in Surgery Today
- Vol. 45 (10) , 1263-1270
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated.
- Open Access
- 10 December 2013
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 8 (1) , 226
Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients
- 10 December 2013
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 8 (1) , 226
Open AccessEfficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients
- 30 June 2012
- Published by Elsevier in Respiratory Investigation
- Vol. 50 (2) , 46-53
Evaluation of a learning system for endobronchial ultrasound-guided transbronchial needle aspiration
- 30 June 2012
- Published by Elsevier in Respiratory Investigation
- Vol. 50 (2) , 46-53
Evaluation of a learning system for endobronchial ultrasound-guided transbronchial needle aspiration
- Open Access
- 1 January 2012
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 26 (4) , 428-432
Extralobar pulmonary sequestration with anomalous blood supply from the pulmonary artery: A case report and review of the Japanese literature
- 1 January 2012
- Published by Japanese Association for Chest Surgery in The Journal of the Japanese Association for Chest Surgery
- Vol. 26 (4) , 428-432
Open AccessExtralobar pulmonary sequestration with anomalous blood supply from the pulmonary artery: A case report and review of the Japanese literature